-
Published 10/12/2026
Qin F, Pimentel DR, Baka T, Croteau D, Cohen RA, Luptak I, Colucci WS. Sotagliflozin corrects myocardial phenotype, mitochondrial gene expression and oxidative stress in mice with hypertrophic cardiomyopathy. J Mol Cell Cardiol Plus. 2026 Dec; 18:100873. PMID: 42926889.
-
Published 10/22/2025
Baka T, Moore J, Qin F, Yurista SR, Zhang A, He H, Chambers JM, Croteau D, Goel RK, Smith H, Wang MC, Chen CS, Hobai IA, Rombaldova M, Kuda O, Tardiff JC, Balschi JA, Pimentel DR, Seidman CE, Seidman JG, Emili A, Colucci WS, Luptak I. Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model. Eur Heart J. 2025 Oct 22; 46(40):4105-4119. PMID: 40396194.
-
Published 8/20/2025
Izumiya Y, Shiojima I, Sato K, Sawyer DB, Colucci WS, Walsh K. Correction: Vascular Endothelial Growth Factor Blockade Promotes the Transition From Compensatory Cardiac Hypertrophy to Failure in Response to Pressure Overload. Hypertension. 2025 Sep; 82(9):e190. PMID: 40834060.
-
Published 4/9/2025
Chambers JM, Croteau D, Pimentel DR, Gower AC, Panagia M, Baka T, Qin F, Luptak I, Colucci WS. SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in Gaq-mice. J Mol Cell Cardiol Plus. 2025 Jun; 12:100296. PMID: 40291834.
-
Published 1/31/2023
Croteau D, Baka T, Young S, He H, Chambers JM, Qin F, Panagia M, Pimentel DR, Balschi JA, Colucci WS, Luptak I. SGLT2 inhibitor ertugliflozin decreases elevated intracellular sodium, and improves energetics and contractile function in diabetic cardiomyopathy. Biomed Pharmacother. 2023 Apr; 160:114310. PMID: 36731341.